GlassScriptPhysician profile
Swapna Omraju
NPI 1891931713
$9,590.58
in general payments reported to CMS, 2019-2025
48 companies · $1,919 in 2025
The $1,919 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $785 · 2020: $788 · 2021: $1,158 · 2022: $841 · 2023: $1,925 · 2024: $2,176 · 2025: $1,919.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,019.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,019.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,237.97 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,031.64 | 2019-2025 | |
| Lilly USA, LLC | $865.31 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Abbvie INC. | $820.85 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $760.35 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $609.80 | 2019-2025 | Repatha, Evenity, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $600.03 | 2019-2025 | Jardiance |
| Exact Sciences Corporation | $337.76 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $283.29 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Esperion Therapeutics, INC. | $258.33 | 2022-2025 | Nexletol |
| E.R. Squibb & Sons, L.L.C. | $201.07 | 2019-2024 | Eliquis |
| Takeda Pharmaceuticals U.S.A., INC. | $195.10 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $180.83 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $175.77 | 2020-2025 | Xifaxan |
| Astellas Pharma US INC | $163.55 | 2022-2025 | Veozah, Myrbetriq |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $160.50 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $139.67 | 2019-2024 | Spravato |
| Dexcom, INC. | $133.96 | 2023-2025 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $129.84 | 2023-2024 | Gemtesa |
| Abbott Laboratories | $119.68 | 2022-2025 | Freestyle Libre 3 |
| Biohaven Pharmaceuticals, INC. | $107.29 | 2020-2021 | |
| Shield Therapeutics INC | $103.88 | 2025 | |
| Medtronic, INC. | $95.76 | 2024-2025 | Intellis Adaptivestim |
| Bayer Healthcare Pharmaceuticals INC. | $89.32 | 2022-2023 | |
| Vivus LLC | $88.26 | 2019-2021 | |
| Axsome Therapeutics, INC. | $78.56 | 2024-2025 | Auvelity |
| Merck Sharp & Dohme LLC | $71.07 | 2019-2021 | |
| Phathom Pharmaceuticals, INC. | $66.41 | 2024 | Voquezna |
| Amarin Pharma, INC. | $56.27 | 2020-2021 | |
| Cequr Corporation | $50.00 | 2025 | Cequr Simplicity |
| Boston Scientific Corporation | $40.75 | 2019-2023 | Wavewriter Alpha Prime 16 |
| Gilead Sciences, INC. | $30.99 | 2020-2021 | |
| Arbor Pharmaceuticals, INC. | $30.54 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $24.69 | 2019-2021 | |
| Intuity Medical INC | $23.65 | 2022 | |
| Sanofi-Aventis U.S. LLC | $22.41 | 2024 | |
| Dynavax Technologies Corporation | $22.23 | 2024 | Heplisav-B |
| Daiichi Sankyo INC. | $20.60 | 2025 | Injectafer |
| Lundbeck LLC | $19.92 | 2023 | Vyepti |
| Idorsia Pharmaceuticals US INC | $18.71 | 2024 | Quviviq |
| Spinal Simplicity, LLC | $18.64 | 2023 | Ha Minuteman G3-R |
| Edwards Lifesciences Corporation | $18.43 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Jazz Pharmaceuticals INC. | $17.47 | 2019 | |
| Alkermes, INC. | $16.53 | 2024 | Vivitrol |
| Almatica Pharma LLC | $15.02 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.13 | 2025 | Caplyta |
| Kowa Pharmaceuticals America, INC. | $12.40 | 2020 | |
| Hikma Pharmaceuticals USA | $11.35 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Swapna Omraju listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.